Exchange: NYSE·Updated 07:30 PM EDT

NUVB News

News
all
press releases
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is...
Cramer calls Nuvation Bio a pure spec, prefers CoreWeave over IREN, is unsure on Seneca, cautious on NuScale, and approves Box.read more...
Benzinga
More News
Cramer's lightning round: Nuvation Bio 'is a pure spec'
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed...
CNBC: Mad Money with Jim Cramer
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nuvation Bio (NUVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Nuvation Bio to Participate in Upcoming Investor Conferences
Nuvation Bio to Participate in Upcoming Investor Conferences Nuvation Bio to Participate in Upcoming Investor Conferences PR Newswire NEW YORK, Sept. 2, 2026 NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest...
PR Newswire
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why
Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma PR Newswire NEW YORK, Aug. 20, 2026 Designation offers pathway to expedite regulatory review...
PR Newswire
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know
The mean of analysts' price targets for Nuvation Bio (NUVB) points to a 105.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Nuvation Bio (NUVB) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +16.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update PR Newswire NEW YORK, Aug. 6, 2026 Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in...
PR Newswire

Advertisement|Remove ads.